Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

Chondrial Therapeutics' lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia

Companies to host conference call today at 8:30 a.m. ET


BOSTON and BALA CYNWYD, Pa., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) and Chondrial Therapeutics, Inc., today announced they have entered into a definitive merger agreement under which Chondrial will become a wholly-owned subsidiary of Zafgen and the stockholders of Chondrial Therapeutics will become the majority owners of Zafgen’s outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.

View the entire Press Release Here

SHARE

FacebookTwitterLinkedInYoutube
Science B.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator